Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
Juan C. Osorio, Ai Ni, Jamie E. Chaft et al. · Annals of Oncology · 2016
Cited by 659 works. doi:10.1093/annonc/mdw640 Open-access PDF
Authors
- Juan C. Osorio
- Ai Ni
- Jamie E. Chaft
- Rachael Pollina
- Mary Kate Kasler
- Lajhem Cambridge
- Humaira Rizvi
- Jedd D. Wolchok
- Taha Merghoub
- Charles M. Rudin
- Stephanie A. Fish
- Matthew David Hellmann
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
- Serum TSH, T 4 , and Thyroid Antibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
- Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes